Antonino Scimone

428 total citations
22 papers, 327 citations indexed

About

Antonino Scimone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Antonino Scimone has authored 22 papers receiving a total of 327 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in Antonino Scimone's work include Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Antonino Scimone is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Lung Cancer Research Studies (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Antonino Scimone collaborates with scholars based in Italy, United States and Belgium. Antonino Scimone's co-authors include Vincenzo Adamo, Tindara Franchina, Alessandro Russo, Giuseppina Rosaria Rita Ricciardi, Giuseppa Ferraro, Alessandra Battaglia, Antonio Giordano, Mariangela Zanghì, Rosa Berenato and Antonio Picone and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Cellular Physiology.

In The Last Decade

Antonino Scimone

19 papers receiving 320 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Antonino Scimone Italy 9 221 165 72 45 39 22 327
Aaron E. Sosa Spain 8 194 0.9× 84 0.5× 85 1.2× 31 0.7× 30 0.8× 13 275
J. Casal Spain 10 195 0.9× 170 1.0× 40 0.6× 30 0.7× 43 1.1× 29 327
Carmen G. Rea Italy 7 207 0.9× 143 0.9× 92 1.3× 23 0.5× 69 1.8× 15 322
Α. Kotsakis Greece 11 223 1.0× 147 0.9× 132 1.8× 17 0.4× 53 1.4× 23 338
Lorenz Jost Switzerland 8 142 0.6× 102 0.6× 79 1.1× 49 1.1× 28 0.7× 11 342
Gary P. Gamble United States 7 260 1.2× 470 2.8× 177 2.5× 93 2.1× 71 1.8× 9 636
Changli Wang China 13 346 1.6× 450 2.7× 89 1.2× 37 0.8× 114 2.9× 29 522
Teruyoshi Ishida Japan 7 174 0.8× 235 1.4× 91 1.3× 32 0.7× 19 0.5× 10 348
Xu-Shan Sun France 7 124 0.6× 80 0.5× 36 0.5× 36 0.8× 22 0.6× 13 193
Aya El Helali Hong Kong 9 108 0.5× 59 0.4× 94 1.3× 34 0.8× 53 1.4× 34 288

Countries citing papers authored by Antonino Scimone

Since Specialization
Citations

This map shows the geographic impact of Antonino Scimone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonino Scimone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonino Scimone more than expected).

Fields of papers citing papers by Antonino Scimone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonino Scimone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonino Scimone. The network helps show where Antonino Scimone may publish in the future.

Co-authorship network of co-authors of Antonino Scimone

This figure shows the co-authorship network connecting the top 25 collaborators of Antonino Scimone. A scholar is included among the top collaborators of Antonino Scimone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonino Scimone. Antonino Scimone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cappuzzo, Federico, Giulia Pasello, Angelo Delmonte, et al.. (2022). Combi-TED: A multicenter, phase II, open-label, randomized trial evaluating efficacy of OSE2021 plus docetaxel or OSE2021 plus nivolumab as second-line therapy in metastatic NSCLC progressing after first-line chemo-immunotherapy.. Journal of Clinical Oncology. 40(16_suppl). TPS9140–TPS9140. 1 indexed citations
2.
Russo, Alessandro, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.. (2019). Dynamic changes of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lactate dehydrogenase (LDH) during treatment with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 37(15_suppl). 2596–2596. 6 indexed citations
3.
Russo, Alessandro, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.. (2018). Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. Journal of Cellular Physiology. 233(10). 6337–6343. 90 indexed citations
4.
5.
6.
Russo, Alessandro, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.. (2017). Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer. Oncotarget. 8(5). 8717–8725. 11 indexed citations
7.
Russo, Alessandro, Tindara Franchina, Giuseppina Rosaria Rita Ricciardi, et al.. (2016). Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Review of Anticancer Therapy. 16(6). 615–623. 19 indexed citations
8.
Ricciardi, Giuseppina Rosaria Rita, Alessandro Russo, Tindara Franchina, et al.. (2014). NSCLC and HER2: Between Lights and Shadows. Journal of Thoracic Oncology. 9(12). 1750–1762. 54 indexed citations
9.
Franchina, Tindara, et al.. (2013). 47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?. Lung Cancer. 80. S20–S21.
10.
Adamo, Vincenzo, Tindara Franchina, Bárbara Adamo, et al.. (2009). Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives. Cancer Biology & Therapy. 8(3). 206–212. 8 indexed citations
11.
Maisano, R., et al.. (2008). Oral Vinorelbine as First Line Chemotherapy in Unfit Elderly Patients with Hormone-Refractory Prostate Cancer. Journal of Chemotherapy. 20(3). 368–373. 2 indexed citations
12.
Iorfida, Monica, et al.. (2007). Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Annals of Oncology. 18. vi53–vi57. 33 indexed citations
13.
Paola, Benedetto Di, et al.. (2007). La Geometria, una guida ai suoi contenuti e alla sua didattica. Nova Science Publishers (Nova Science Publishers, Inc.). 1–166. 1 indexed citations
14.
Franchina, Tindara, et al.. (2006). Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. Annals of Oncology. 17. ii73–ii75. 13 indexed citations
15.
Adamo, Vincenzo, Giosafat Spitaleri, Elisabetta Alafaci, et al.. (2005). Phase II Study of Gemcitabine and Cisplatin in Patients with Advanced or Metastatic Bladder Cancer: Long-Term Follow-Up of a 3-Week Regimen. Oncology. 69(5). 391–398. 23 indexed citations
16.
Adamo, Vincenzo, Giuseppa Ferraro, Stefano Pergolizzi, et al.. (2004). Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma. Oral Oncology. 40(5). 525–531. 37 indexed citations
17.
Scimone, Antonino, R. Maisano, Giuseppe Altavilla, et al.. (1999). Etoposide,l-Leucovorin and Fluorouracil (ELF) Regimen in Metastatic Gastric Cancer: A Phase II Study. Journal of Chemotherapy. 11(1). 74–77. 6 indexed citations
18.
Adamo, Vincenzo, R. Maisano, Stefano Pergolizzi, et al.. (1997). Bleomycin, Epirubicin, Carboplatin (BECA) in the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Chemotherapy. 9(1). 72–76. 3 indexed citations
19.
Maisano, R., et al.. (1997). Defibrotide in the prevention of venous irritation by vinorelbine administration.. PubMed. 17(4A). 2775–7. 7 indexed citations
20.
Maisano, R., Vincenzo Adamo, Nicola Settineri, et al.. (1996). Efficacy of two oral dose regimens of granisetron.. PubMed. 15(5B). 2287–90. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron E. Sosa Breakdown of academic impact, for papers by J. Casal Breakdown of academic impact, for papers by Carmen G. Rea Breakdown of academic impact, for papers by Α. Kotsakis Breakdown of academic impact, for papers by Lorenz Jost Breakdown of academic impact, for papers by Gary P. Gamble Breakdown of academic impact, for papers by Changli Wang Breakdown of academic impact, for papers by Teruyoshi Ishida Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Aya El Helali
Rankless by CCL
2026